{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T11:52:28Z","timestamp":1782993148745,"version":"3.54.5"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"2","license":[{"start":{"date-parts":[[2024,11,4]],"date-time":"2024-11-04T00:00:00Z","timestamp":1730678400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,11,4]],"date-time":"2024-11-04T00:00:00Z","timestamp":1730678400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Neurol Sci"],"published-print":{"date-parts":[[2025,2]]},"DOI":"10.1007\/s10072-024-07861-6","type":"journal-article","created":{"date-parts":[[2024,11,4]],"date-time":"2024-11-04T09:24:00Z","timestamp":1730712240000},"page":"951-959","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":8,"title":["Eculizumab in refractory myasthenia gravis: a real-world single-center experience"],"prefix":"10.1007","volume":"46","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-4862-4165","authenticated-orcid":false,"given":"Dario","family":"Ricciardi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8001-0836","authenticated-orcid":false,"given":"Carmen","family":"Erra","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Tuccillo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bernardo Maria","family":"De Martino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra","family":"Fasolino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Habetswallner","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,11,4]]},"reference":[{"key":"7861_CR1","doi-asserted-by":"publisher","unstructured":"Gilhus NE, Verschuuren JJ (2015) Myasthenia gravis: subgroup classification and therapeutic strategies. Lancet Neurol. ;14(10):1023-36. https:\/\/doi.org\/10.1016\/S1474-4422(15)00145-3. PMID: 26376969","DOI":"10.1016\/S1474-4422(15)00145-3"},{"key":"7861_CR2","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.12688\/f1000research.8206.1","volume":"5","author":"WD Phillips","year":"2016","unstructured":"Phillips WD, Vincent A (2016) Pathogenesis of myasthenia gravis: update on disease types, models, and mechanisms. F1000Res 5:1513. https:\/\/doi.org\/10.12688\/f1000research.8206.1","journal-title":"F1000Res"},{"key":"7861_CR3","doi-asserted-by":"publisher","first-page":"175628561774913","DOI":"10.1177\/1756285617749134","volume":"11","author":"R Mantegazza","year":"2018","unstructured":"Mantegazza R, Antozzi C (2018) When myasthenia gravis is deemed refractory: clinical signposts and treatment strategies. Ther Adv Neurol Disord 11:1756285617749134. https:\/\/doi.org\/10.1177\/1756285617749134. Erratum in: Ther Adv Neurol Disord. 2018;11:1756286418765591. PMID: 29403543; PMCID: PMC5791553","journal-title":"Ther Adv Neurol Disord"},{"key":"7861_CR4","doi-asserted-by":"publisher","first-page":"175628641983224","DOI":"10.1177\/1756286419832242","volume":"12","author":"C Schneider-Gold","year":"2019","unstructured":"Schneider-Gold C, Hagenacker T, Melzer N et al (2019) Understanding the burden of refractory myasthenia gravis. Ther Adv Neurol Disord 12:1756286419832242. https:\/\/doi.org\/10.1177\/1756286419832242PMID: 30854027; PMCID: PMC6399761","journal-title":"Ther Adv Neurol Disord"},{"key":"7861_CR5","doi-asserted-by":"publisher","unstructured":"Lehnerer S, Jacobi J, Schilling R et al (2022) Burden of disease in myasthenia gravis: taking the patient\u2019s perspective. J Neurol. ;269(6):3050\u20133063. https:\/\/doi.org\/10.1007\/s00415-021-10891-1. Epub 2021 Nov 20. Erratum in: J Neurol. 2022;269(10):5688\u20135689. PMID: 34800167; PMCID: PMC9120127","DOI":"10.1007\/s00415-021-10891-1"},{"issue":"1","key":"7861_CR6","doi-asserted-by":"publisher","first-page":"172","DOI":"10.1186\/s12883-022-02692-4","volume":"22","author":"L Harris","year":"2022","unstructured":"Harris L, Graham S, MacLachlan S et al (2022) A retrospective longitudinal cohort study of the clinical burden in myasthenia gravis. BMC Neurol 22(1):172. https:\/\/doi.org\/10.1186\/s12883-022-02692-4PMID: 35534810; PMCID: PMC9082838","journal-title":"BMC Neurol"},{"key":"7861_CR7","doi-asserted-by":"publisher","unstructured":"Engel-Nitz NM, Boscoe A, Wolbeck R et al (2018) Burden of illness in patients with treatment refractory myasthenia gravis. Muscle Nerve. Feb 27. https:\/\/doi.org\/10.1002\/mus.26114. Epub ahead of print. PMID: 29486521","DOI":"10.1002\/mus.26114"},{"key":"7861_CR8","doi-asserted-by":"publisher","first-page":"25","DOI":"10.2147\/ITT.S377056","volume":"12","author":"SS Nair","year":"2023","unstructured":"Nair SS, Jacob S (2023) Novel immunotherapies for Myasthenia Gravis. Immunotargets Ther 12:25\u201345. https:\/\/doi.org\/10.2147\/ITT.S377056PMID: 37038596; PMCID: PMC10082579","journal-title":"Immunotargets Ther"},{"issue":"12","key":"7861_CR9","doi-asserted-by":"publisher","first-page":"976","DOI":"10.1016\/S1474-4422(17)30369-1","volume":"16","author":"JF Howard Jr","year":"2017","unstructured":"Howard JF Jr, Utsugisawa K, Benatar M, REGAIN Study Group et al (2017) Safety and efficacy of eculizumab in anti-acetylcholine receptor antibody-positive refractory generalised myasthenia gravis (REGAIN): a phase 3, randomised, double-blind, placebo-controlled, multicentre study. Lancet Neurol 16(12):976\u2013986. https:\/\/doi.org\/10.1016\/S1474-4422(17)30369-1","journal-title":"Lancet Neurol"},{"issue":"1","key":"7861_CR10","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1002\/mus.26447","volume":"60","author":"S Muppidi","year":"2019","unstructured":"Muppidi S, Utsugisawa K, Benatar M et al (2019) Long-term safety and efficacy of eculizumab in generalized myasthenia gravis. Muscle Nerve 60(1):14\u201324. https:\/\/doi.org\/10.1002\/mus.26447","journal-title":"Muscle Nerve"},{"key":"7861_CR11","unstructured":"Alexion Pharmaceuticals Inc.: SOLIRIS\u00ae (Eculizumab) Injection Prescribing Information (2019) https:\/\/alexion.com\/Documents\/SolirisUSPI.pdf Accessed October 2019"},{"key":"7861_CR12","unstructured":"Alexion Europe (2019) Soliris (eculizumab) Summary of Product Characteristics. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/EPAR\/soliris Accessed"},{"key":"7861_CR13","unstructured":"Pharmaceuticals and Medical Devices Agency: Eculizumab (Genetical Recombination) SOLIRIS\u00ae for Intravenous Infusion 300\u00a0mg (Japanese Package Insert), Revised: February 2019 (Version 11) (2019) http:\/\/www.soliris.jp\/common\/pdf\/tempubunsho.pdf Accessed November 2019"},{"issue":"6","key":"7861_CR14","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1002\/mus.27476","volume":"65","author":"S Muppidi","year":"2022","unstructured":"Muppidi S, Silvestri NJ, Tan R et al (2022) Utilization of MG-ADL in myasthenia gravis clinical research and care. Muscle Nerve 65(6):630\u2013639. https:\/\/doi.org\/10.1002\/mus.27476","journal-title":"Muscle Nerve"},{"issue":"10","key":"7861_CR15","doi-asserted-by":"publisher","first-page":"442","DOI":"10.1212\/WNL.0000000000207278","volume":"101","author":"JT Guptill","year":"2023","unstructured":"Guptill JT, Benatar M, Granit V, for MGNet Clinical Trial Outcome Measure Working Group et al (2023) Addressing outcome measure variability in Myasthenia Gravis clinical trials. Neurology 101(10):442\u2013451. https:\/\/doi.org\/10.1212\/WNL.0000000000207278","journal-title":"Neurology"},{"key":"7861_CR16","doi-asserted-by":"publisher","unstructured":"Jaretzki A 3rd, Barohn RJ, Ernstoff RM et al (2000) Myasthenia gravis: recommendations for clinical research standards. Task Force of the Medical Scientific Advisory Board of the Myasthenia Gravis Foundation of America. Neurology. ;55(1):16\u201323. https:\/\/doi.org\/10.1212\/wnl.55.1.16. PMID: 10891897","DOI":"10.1212\/wnl.55.1.16"},{"issue":"4","key":"7861_CR17","doi-asserted-by":"publisher","first-page":"e610","DOI":"10.1212\/WNL.0000000000011207","volume":"96","author":"R Mantegazza","year":"2021","unstructured":"Mantegazza R, Wolfe GI, Muppidi S et al (2021) REGAIN Study Group. Post-intervention status in patients with refractory myasthenia gravis treated with Eculizumab during REGAIN and its open-label extension. Neurology 96(4):e610\u2013e618. https:\/\/doi.org\/10.1212\/WNL.0000000000011207","journal-title":"Neurology"},{"issue":"3","key":"7861_CR18","doi-asserted-by":"publisher","first-page":"269","DOI":"10.3233\/JND-190464","volume":"7","author":"S Datta","year":"2020","unstructured":"Datta S, Singh S, Govindarajan R (2020) Retrospective analysis of Eculizumab in patients with acetylcholine receptor antibody-negative Myasthenia gravis: a Case Series. J Neuromuscul Dis 7(3):269\u2013277. https:\/\/doi.org\/10.3233\/JND-190464PMID: 32444555; PMCID: PMC7369065","journal-title":"J Neuromuscul Dis"},{"issue":"2","key":"7861_CR19","doi-asserted-by":"publisher","first-page":"287","DOI":"10.3233\/JND-200584","volume":"8","author":"N Katyal","year":"2021","unstructured":"Katyal N, Narula N, Govindarajan R (2021) Clinical experience with Eculizumab in treatment-refractory acetylcholine receptor antibody-positive generalized Myasthenia Gravis. J Neuromuscul Dis 8(2):287\u2013294. https:\/\/doi.org\/10.3233\/JND-200584PMID: 33325394; PMCID: PMC8075396","journal-title":"J Neuromuscul Dis"},{"key":"7861_CR20","doi-asserted-by":"publisher","first-page":"175628642090420","DOI":"10.1177\/1756286420904207","volume":"13","author":"M Oyama","year":"2020","unstructured":"Oyama M, Okada K, Masuda M et al (2020) Suitable indications of eculizumab for patients with refractory generalized myasthenia gravis. Ther Adv Neurol Disord 13:1756286420904207. https:\/\/doi.org\/10.1177\/1756286420904207PMID: 32215054; PMCID: PMC7081459","journal-title":"Ther Adv Neurol Disord"},{"issue":"3","key":"7861_CR21","doi-asserted-by":"publisher","first-page":"348","DOI":"10.1002\/mus.27656","volume":"66","author":"J Suh","year":"2022","unstructured":"Suh J, Clarke V, Amato AA et al (2022) Safety and outcomes of eculizumab for acetylcholine receptor-positive generalized myasthenia gravis in clinical practice. Muscle Nerve 66(3):348\u2013353. https:\/\/doi.org\/10.1002\/mus.27656Epub 2022 Jun 27. PMID: 35684980","journal-title":"Muscle Nerve"},{"issue":"9","key":"7861_CR22","doi-asserted-by":"publisher","first-page":"6209","DOI":"10.1007\/s00415-024-12588-7","volume":"271","author":"C Pane","year":"2024","unstructured":"Pane C, Di Stefano V, Cuomo N, Sarnataro A, Vinciguerra C, Bevilacqua L, Brighina F, Rini N, Puorro G, Marsili A, Garibaldi M, Fionda L, Sacc\u00e0 F (2024) A real-life experience with eculizumab and efgartigimod in generalized myasthenia gravis patients. J Neurol 271(9):6209\u20136219. https:\/\/doi.org\/10.1007\/s00415-024-12588-7Epub 2024 Jul 30. PMID: 39080054; PMCID: PMC11377599","journal-title":"J Neurol"},{"issue":"10","key":"7861_CR23","doi-asserted-by":"publisher","first-page":"3707","DOI":"10.1007\/s10072-023-06900-y","volume":"44","author":"C Vinciguerra","year":"2023","unstructured":"Vinciguerra C, Bevilacqua L, Toriello A et al (2023) Starting eculizumab as rescue therapy in refractory myasthenic crisis. Neurol Sci 44(10):3707\u20133709. https:\/\/doi.org\/10.1007\/s10072-023-06900-yEpub 2023 Jun 12. PMID: 37306795","journal-title":"Neurol Sci"},{"issue":"9","key":"7861_CR24","doi-asserted-by":"publisher","first-page":"3125","DOI":"10.1007\/s00415-021-10428-6","volume":"268","author":"U Hofstadt-van Oy","year":"2021","unstructured":"Hofstadt-van Oy U, Stankovic S, Kelbel C et al (2021) Complement inhibition initiated recovery of a severe myasthenic crisis with COVID-19. J Neurol 268(9):3125\u20133128. https:\/\/doi.org\/10.1007\/s00415-021-10428-6Epub 2021 Feb 4. PMID: 33537898; PMCID: PMC7857861","journal-title":"J Neurol"},{"issue":"2","key":"7861_CR25","doi-asserted-by":"publisher","first-page":"212","DOI":"10.1002\/mus.27326","volume":"64","author":"U Usman","year":"2021","unstructured":"Usman U, Chrisman C, Houston D, Haws CC, Wang A, Muley S (2021) The use of eculizumab in ventilator-dependent myasthenia gravis patients. Muscle Nerve 64(2):212\u2013215","journal-title":"Muscle Nerve"}],"container-title":["Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-024-07861-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10072-024-07861-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10072-024-07861-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,1,27]],"date-time":"2025-01-27T09:14:19Z","timestamp":1737969259000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10072-024-07861-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,11,4]]},"references-count":25,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2025,2]]}},"alternative-id":["7861"],"URL":"https:\/\/doi.org\/10.1007\/s10072-024-07861-6","relation":{},"ISSN":["1590-1874","1590-3478"],"issn-type":[{"value":"1590-1874","type":"print"},{"value":"1590-3478","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,11,4]]},"assertion":[{"value":"22 September 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 October 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 November 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"This study was conducted in accordance with ethical principles that have their origin in the Declaration of Helsinki and that are consistent with Good Clinical Practice. Ethical approval was waived by the local Ethics Committee and all the procedures being performed were part of the routine care. All patients provided written informed consent. We confirm that we have read the Journal\u2019s position on issues involved in ethical publication and affirm that this report is consistent with those guidelines.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"Dario Ricciardi has received travel funding and speaker honoraria from Alexion, UCB, Argenx. This author has no potential conflict of interest to disclose. Carmen Erra has received travel funding and speaker honoraria from Alexion, UCB, Argenx, Anlylam, CLS Bhering. This author has no potential conflict of interest to disclose. Francesco Tuccillo has received travel funding and speaker honoraria from Alexion, UCB, Argenx. This author has no potential conflict of interest to disclose. Bernardo Maria De Martino has received travel funding and speaker honoraria from Alexion, UCB, Argenx. This author has no potential conflict of interest to disclose. Alessandra Fasolino has no financial disclosure. This author has no potential conflict of interest to disclose. Francesco Habetswallner has received travel funding and speaker honoraria from Alexion, UCB, Argenx. This author has no potential conflict of interest to disclose.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}